Rigel Pharmaceuticals | RIGL - Заемный капитал





Заемный капитал Изменить Дата
Agenus USD 153.98M 15.68M 2026-03
Amgen USD 51.86B 27M 2026-06
Arrowhead Research USD 824.07M 401.34M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Daiichi Sankyo JPY 500B 199.92B 2026-06
Eli Lilly USD 47.86B 8.49B 2026-06
Halozyme Therapeutics USD 1.94B 1.79M 2026-06
Heron Therapeutics USD 140.64M 975K 2025-12
Intrexon USD 0 198.67M 2024-06
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
Karyopharm Therapeutics USD 264.49M 13.73M 2026-03
Ligand Pharmaceuticals USD 446.9M 704K 2026-03
MacroGenics USD 68.71M 1.29M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Pfizer USD 60.5B 70M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Rigel Pharmaceuticals USD 0 0 2024-09
Sangamo BioSciences USD 0 0 2022-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Veracyte USD 0 0 2025-03